1
|
Liu R, Duan W, Yan W, Zhang J, Cheng J. Design and synthesis of tri-substituted pyrimidine derivatives as bifunctional tumor immunotherapeutic agents targeting both A2A adenosine receptors and histone deacetylases. CHINESE CHEM LETT 2023. [DOI: 10.1016/j.cclet.2023.108136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
2
|
Stampelou M, Suchankova A, Tzortzini E, Dhingra L, Barkan K, Lougiakis N, Marakos P, Pouli N, Ladds G, Kolocouris A. Dual A1/A3 Adenosine Receptor Antagonists: Binding Kinetics and Structure-Activity Relationship Studies Using Mutagenesis and Alchemical Binding Free Energy Calculations. J Med Chem 2022; 65:13305-13327. [PMID: 36173355 DOI: 10.1021/acs.jmedchem.2c01123] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Drugs targeting adenosine receptors (AR) can provide treatment for diseases. We report the identification of 7-(phenylamino)-pyrazolo[3,4-c]pyridines L2-L10, A15, and A17 as low-micromolar to low-nanomolar A1R/A3R dual antagonists, with 3-phenyl-5-cyano-7-(trimethoxyphenylamino)-pyrazolo[3,4-c]pyridine (A17) displaying the highest affinity at both receptors with a long residence time of binding, as determined using a NanoBRET-based assay. Two binding orientations of A17 produce stable complexes inside the orthosteric binding area of A1R in molecular dynamics (MD) simulations, and we selected the most plausible orientation based on the agreement with alanine mutagenesis supported by affinity experiments. Interestingly, for drug design purposes, the mutation of L2506.51 to alanine increased the binding affinity of A17 at A1R. We explored the structure-activity relationships against A1R using alchemical binding free energy calculations with the thermodynamic integration coupled with the MD simulation (TI/MD) method, applied on the whole G-protein-coupled receptor-membrane system, which showed a good agreement (r = 0.73) between calculated and experimental relative binding free energies.
Collapse
Affiliation(s)
- Margarita Stampelou
- Laboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, 15771 Athens, Greece
| | - Anna Suchankova
- Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, U.K
| | - Efpraxia Tzortzini
- Laboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, 15771 Athens, Greece
| | - Lakshiv Dhingra
- Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, U.K
| | - Kerry Barkan
- Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, U.K
| | - Nikolaos Lougiakis
- Laboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, 15771 Athens, Greece
| | - Panagiotis Marakos
- Laboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, 15771 Athens, Greece
| | - Nicole Pouli
- Laboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, 15771 Athens, Greece
| | - Graham Ladds
- Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, U.K
| | - Antonios Kolocouris
- Laboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, 15771 Athens, Greece
| |
Collapse
|
3
|
Mishra CB, Kumari S, Angeli A, Bua S, Mongre RK, Tiwari M, Supuran CT. Discovery of Potent Carbonic Anhydrase Inhibitors as Effective Anticonvulsant Agents: Drug Design, Synthesis, and In Vitro and In Vivo Investigations. J Med Chem 2021; 64:3100-3114. [PMID: 33721499 DOI: 10.1021/acs.jmedchem.0c01889] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Two sets of benzenesulfonamide-based effective human carbonic anhydrase (hCA) inhibitors have been developed using the tail approach. The inhibitory action of these novel molecules was examined against four isoforms: hCA I, hCA II, hCA VII, and hCA XII. Most of the molecules disclosed low to medium nanomolar range inhibition against all tested isoforms. Some of the synthesized derivatives selectively inhibited the epilepsy-involved isoforms hCA II and hCA VII, showing low nanomolar affinity. The anticonvulsant activity of selected sulfonamides was assessed using the maximal electroshock seizure (MES) and subcutaneous pentylenetetrazole (sc-PTZ) in vivo models of epilepsy. These potent CA inhibitors effectively inhibited seizures in both epilepsy models. The most effective compounds showed long duration of action and abolished MES-induced seizures up to 6 h after drug administration. These sulfonamides were found to be orally active anticonvulsants, being nontoxic in neuronal cell lines and in animal models.
Collapse
Affiliation(s)
- Chandra Bhushan Mishra
- College of Pharmacy, Sookmyung Women's University, Cheongpa-ro 47-gil 100, Yongsan-gu, Seoul 04310, Republic of Korea
| | - Shikha Kumari
- Bio-Organic Chemistry Laboratory, Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi 110007, India
| | - Andrea Angeli
- Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Universitàdegli Studi di Firenze, Florence 50019, Italy
| | - Silvia Bua
- Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Universitàdegli Studi di Firenze, Florence 50019, Italy
| | - Raj Kumar Mongre
- College of Pharmacy, Sookmyung Women's University, Cheongpa-ro 47-gil 100, Yongsan-gu, Seoul 04310, Republic of Korea
| | - Manisha Tiwari
- Bio-Organic Chemistry Laboratory, Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi 110007, India
| | - Claudiu T Supuran
- Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Universitàdegli Studi di Firenze, Florence 50019, Italy
| |
Collapse
|
4
|
|
5
|
Boualia I, Derabli C, Boulcina R, Bensouici C, Yildirim M, Birinci Yildirim A, Mokrani EH, Debache A. Synthesis, molecular docking studies, and biological evaluation of novel alkyl bis(4-amino-5-cyanopyrimidine) derivatives. Arch Pharm (Weinheim) 2019; 352:e1900027. [PMID: 31448454 DOI: 10.1002/ardp.201900027] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Revised: 07/25/2019] [Accepted: 07/26/2019] [Indexed: 11/08/2022]
Abstract
A series of bis(4-amino-5-cyano-pyrimidines) was synthesized and evaluated as dual inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). To further explore the multifunctional properties of the new derivatives, their antioxidant and antibacterial activities were also tested. The results showed that most of these compounds could effectively inhibit AChE and BChE. Particularly, compound 7c exhibited the best AChE inhibitory activity (IC50 = 5.72 ± 1.53 μM), whereas compound 7h was identified as the most potent BChE inhibitor (IC50 = 12.19 ± 0.57 μM). Molecular modeling study revealed that compounds 7c, 7f, and 7b showed a higher inhibitory activity than that of galantamine against both AChE and BChE. Anticholinesterase activity of compounds 7h, 7b, and 7c was significant in vitro and in silico for both enzymes, since these compounds have hydrophobic rings (Br-phenyl, dimethyl, and methoxyphenyl), which bind very well in both sites. In addition to cholinesterase inhibitory activities, these compounds showed different levels of antioxidant activities. Indeed, in the superoxide-dimethyl sulfoxide alkaline assay, compound 7j showed very high inhibition (IC50 = 0.37 ± 0.28 μM). Also, compound 7l exhibited strong and good antibacterial activity against Staphylococcus epidermidis and Staphylococcus aureus, respectively. Taking into account the results of biological evaluation, further modifications will be designed to increase potency on different targets. In this study, the obtained results can be a new starting point for further development of multifunctional agents for the treatment of Alzheimer's disease.
Collapse
Affiliation(s)
- Imen Boualia
- Laboratory of Synthesis of Molecules with Biological Interest, Mentouri-Constantine University, Constantine, Algeria
| | - Chamseddine Derabli
- Laboratory of Synthesis of Molecules with Biological Interest, Mentouri-Constantine University, Constantine, Algeria
| | - Raouf Boulcina
- Laboratory of Synthesis of Molecules with Biological Interest, Mentouri-Constantine University, Constantine, Algeria.,Faculty of Technology, Batna 2 University, Batna, Algeria
| | | | - Muhammet Yildirim
- Department of Chemistry, Faculty of Sciences and Arts, Abant Izzet Baysal University, Bolu, Turkey
| | - Arzu Birinci Yildirim
- Department of Field Crops, Faculty of Agriculture and Natural Sciences, Abant İzzet Baysal University, Bolu, Turkey
| | - El Hassen Mokrani
- Department of Biochemistry and Cellular and Molecular Biology, Laboratory of Applied Biochemistry, Faculty of Natural and Life Sciences, Mentouri-Constantine University, Constantine, Algeria
| | - Abdelmadjid Debache
- Laboratory of Synthesis of Molecules with Biological Interest, Mentouri-Constantine University, Constantine, Algeria
| |
Collapse
|
6
|
Basu S, Barawkar DA, Ramdas V, Naykodi M, Shejul YD, Patel M, Thorat S, Panmand A, Kashinath K, Bonagiri R, Prasad V, Bhat G, Quraishi A, Chaudhary S, Magdum A, Meru AV, Ghosh I, Bhamidipati RK, Raje AA, Madgula VLM, De S, Rouduri SR, Palle VP, Chugh A, Hariharan N, Mookhtiar KA. Discovery of Potent and Selective A 2A Antagonists with Efficacy in Animal Models of Parkinson's Disease and Depression. ACS Med Chem Lett 2017; 8:835-840. [PMID: 28835798 DOI: 10.1021/acsmedchemlett.7b00175] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2017] [Accepted: 07/05/2017] [Indexed: 12/15/2022] Open
Abstract
Adenosine A2A receptor (A2AAdoR) antagonism is a nondopaminergic approach to Parkinson's disease treatment that is under development. Earlier we had reported the therapeutic potential of 7-methoxy-4-morpholino-benzothiazole derivatives as A2AAdoR antagonists. We herein described a novel series of [1,2,4]triazolo[5,1-f]purin-2-one derivatives that displays functional antagonism of the A2A receptor with a high degree of selectivity over A1, A2B, and A3 receptors. Compounds from this new scaffold resulted in the discovery of highly potent, selective, stable, and moderate brain penetrating compound 33. Compound 33 endowed with satisfactory in vitro and in vivo pharmacokinetics properties. Compound 33 demonstrated robust oral efficacies in two commonly used models of Parkinson's disease (haloperidol-induced catalepsy and 6-OHDA lesioned rat models) and depression (TST and FST mice models).
Collapse
Affiliation(s)
- Sujay Basu
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Dinesh A. Barawkar
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Vidya Ramdas
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Minakshi Naykodi
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Yogesh D. Shejul
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Meena Patel
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Sachin Thorat
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Anil Panmand
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - K. Kashinath
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Rajesh Bonagiri
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Vandna Prasad
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Ganesh Bhat
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Azfar Quraishi
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Sumit Chaudhary
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Amol Magdum
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Ashwinkumar V. Meru
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Indraneel Ghosh
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Ravi K. Bhamidipati
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Amol A. Raje
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Vamsi L. M. Madgula
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Siddhartha De
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Sreekanth R. Rouduri
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Venkata P. Palle
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Anita Chugh
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Narayanan Hariharan
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Kasim A. Mookhtiar
- Advinus Therapeutics Ltd., Drug Discovery Facility, Quantum Towers, Plot-9,
Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| |
Collapse
|
7
|
Basu S, Barawkar DA, Thorat S, Shejul YD, Patel M, Naykodi M, Jain V, Salve Y, Prasad V, Chaudhary S, Ghosh I, Bhat G, Quraishi A, Patil H, Ansari S, Menon S, Unadkat V, Thakare R, Seervi MS, Meru AV, De S, Bhamidipati RK, Rouduri SR, Palle VP, Chug A, Mookhtiar KA. Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A 2A Receptor Antagonists and Their Biological Evaluation. J Med Chem 2017; 60:681-694. [PMID: 28055204 DOI: 10.1021/acs.jmedchem.6b01584] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Our initial structure-activity relationship studies on 7-methoxy-4-morpholino-benzothiazole derivatives featured by aryloxy-2-methylpropanamide moieties at the 2-position led to identification of compound 25 as a potent and selective A2A adenosine receptor (A2AAdoR) antagonist with reasonable ADME and pharmacokinetic properties. However, poor intrinsic solubility and low to moderate oral bioavailability made this series unsuitable for further development. Further optimization using structure-based drug design approach resulted in discovery of potent and selective adenosine A2A receptor antagonists bearing substituted 1-methylcyclohexyl-carboxamide groups at position 2 of the benzothiazole scaffold and endowed with better solubility and oral bioavailability. Compounds 41 and 49 demonstrated a number of positive attributes with respect to in vitro ADME properties. Both compounds displayed good pharmacokinetic properties with 63% and 61% oral bioavailability, respectively, in rat. Further, compound 49 displayed oral efficacy in 6-OHDA lesioned rat model of Parkinson diseases.
Collapse
Affiliation(s)
- Sujay Basu
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Dinesh A Barawkar
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Sachin Thorat
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Yogesh D Shejul
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Meena Patel
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Minakshi Naykodi
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Vaibhav Jain
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Yogesh Salve
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Vandna Prasad
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Sumit Chaudhary
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Indraneel Ghosh
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Ganesh Bhat
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Azfar Quraishi
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Harish Patil
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Shariq Ansari
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Suraj Menon
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Vishal Unadkat
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Rhishikesh Thakare
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Madhav S Seervi
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Ashwinkumar V Meru
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Siddhartha De
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Ravi K Bhamidipati
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Sreekanth R Rouduri
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Venkata P Palle
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Anita Chug
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| | - Kasim A Mookhtiar
- Drug Discovery Facility, Advinus Therapeutics Ltd. , Quantum Towers, Plot-9, Phase-I, Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411 057, India
| |
Collapse
|
8
|
Yang Z, Li L, Zheng J, Ma H, Tian S, Li J, Zhang H, Zhen X, Zhang X. Identification of a New Series of Potent Adenosine A 2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson's Disease. ACS Chem Neurosci 2016; 7:1575-1584. [PMID: 27569066 DOI: 10.1021/acschemneuro.6b00218] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Adenosine receptor A2A antagonists have emerged as potential treatment for Parkinson's disease in the past decade. We have recently reported a series of adenosine receptor antagonists using heterocycles as bioisosteres for a potentially unstable acetamide. These compounds, while showing excellent potency and ligand efficiency, suffered from moderate cytochrome P450 inhibition and high clearance. Here we report a new series of adenosine receptor A2A antagonists based on a 4-amino-5-carbonitrile pyrimidine template. Compounds from this new template exhibit excellent potency and ligand efficiency with low cytochrome P450 inhibition. Although the clearance remains moderate to high, the leading compound, when dosed orally as low as 3 mg/kg, demonstrated excellent efficacy in the haloperidol induced catalepsy rat model for Parkinson's disease.
Collapse
Affiliation(s)
- Zhaohui Yang
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psychiatric-Diseases
and College of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Linlang Li
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psychiatric-Diseases
and College of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Jiyue Zheng
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psychiatric-Diseases
and College of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Haikuo Ma
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psychiatric-Diseases
and College of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Sheng Tian
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psychiatric-Diseases
and College of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Jiajun Li
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psychiatric-Diseases
and College of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Hongjian Zhang
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psychiatric-Diseases
and College of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Xuechu Zhen
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psychiatric-Diseases
and College of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Xiaohu Zhang
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psychiatric-Diseases
and College of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| |
Collapse
|
9
|
Norcross NR, Baragaña B, Wilson C, Hallyburton I, Osuna-Cabello M, Norval S, Riley J, Stojanovski L, Simeons FRC, Porzelle A, Grimaldi R, Wittlin S, Duffy S, Avery VM, Meister S, Sanz L, Jiménez-Díaz B, Angulo-Barturen I, Ferrer S, Martínez MS, Gamo FJ, Frearson JA, Gray DW, Fairlamb AH, Winzeler EA, Waterson D, Campbell SF, Willis P, Read KD, Gilbert IH. Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials. J Med Chem 2016; 59:6101-20. [PMID: 27314305 PMCID: PMC4947981 DOI: 10.1021/acs.jmedchem.6b00028] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
![]()
In this paper we describe the optimization
of a phenotypic hit
against Plasmodium falciparum, based on a trisubstituted
pyrimidine scaffold. This led to compounds with good pharmacokinetics
and oral activity in a P. berghei mouse model of
malaria. The most promising compound (13) showed a reduction
in parasitemia of 96% when dosed at 30 mg/kg orally once a day for
4 days in the P. berghei mouse model of malaria.
It also demonstrated a rapid rate of clearance of the erythrocytic
stage of P. falciparum in the SCID mouse model with
an ED90 of 11.7 mg/kg when dosed orally. Unfortunately,
the compound is a potent inhibitor of cytochrome P450 enzymes, probably
due to a 4-pyridyl substituent. Nevertheless, this is a lead molecule
with a potentially useful antimalarial profile, which could either
be further optimized or be used for target hunting.
Collapse
Affiliation(s)
- Neil R Norcross
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Beatriz Baragaña
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Caroline Wilson
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Irene Hallyburton
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Maria Osuna-Cabello
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Suzanne Norval
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Jennifer Riley
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Laste Stojanovski
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Frederick R C Simeons
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Achim Porzelle
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Raffaella Grimaldi
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Sergio Wittlin
- Swiss Tropical and Public Health Institute (Swiss TPH) , Socinstrasse 57, 4051 Basel, Switzerland.,University of Basel , CH-4003 Basel, Switzerland
| | - Sandra Duffy
- Discovery Biology, Eskitis Institute for Drug Discovery, Griffith University , Nathan, Queensland 4111, Australia
| | - Vicky M Avery
- Discovery Biology, Eskitis Institute for Drug Discovery, Griffith University , Nathan, Queensland 4111, Australia
| | - Stephan Meister
- Department of Pediatrics, University of California, San Diego School of Medicine , 9500 Gilman Drive, 0741, La Jolla, California 92093, United States
| | - Laura Sanz
- Diseases of the Developing World-Tres Cantos Medicines Development Campus, GlaxoSmithKline , c/Severo Ochoa, 2, Tres Cantos, 28760, Madrid, Spain
| | - Belén Jiménez-Díaz
- Diseases of the Developing World-Tres Cantos Medicines Development Campus, GlaxoSmithKline , c/Severo Ochoa, 2, Tres Cantos, 28760, Madrid, Spain
| | - Iñigo Angulo-Barturen
- Diseases of the Developing World-Tres Cantos Medicines Development Campus, GlaxoSmithKline , c/Severo Ochoa, 2, Tres Cantos, 28760, Madrid, Spain
| | - Santiago Ferrer
- Diseases of the Developing World-Tres Cantos Medicines Development Campus, GlaxoSmithKline , c/Severo Ochoa, 2, Tres Cantos, 28760, Madrid, Spain
| | - María Santos Martínez
- Diseases of the Developing World-Tres Cantos Medicines Development Campus, GlaxoSmithKline , c/Severo Ochoa, 2, Tres Cantos, 28760, Madrid, Spain
| | - Francisco Javier Gamo
- Diseases of the Developing World-Tres Cantos Medicines Development Campus, GlaxoSmithKline , c/Severo Ochoa, 2, Tres Cantos, 28760, Madrid, Spain
| | - Julie A Frearson
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - David W Gray
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Alan H Fairlamb
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Elizabeth A Winzeler
- Department of Pediatrics, University of California, San Diego School of Medicine , 9500 Gilman Drive, 0741, La Jolla, California 92093, United States
| | - David Waterson
- Medicines for Malaria Venture , International Center Cointrin, Entrance G, 3rd Floor, Route de Pré-Bois 20, P.O. Box 1826, CH-1215, Geneva 15, Switzerland
| | - Simon F Campbell
- Medicines for Malaria Venture , International Center Cointrin, Entrance G, 3rd Floor, Route de Pré-Bois 20, P.O. Box 1826, CH-1215, Geneva 15, Switzerland
| | - Paul Willis
- Medicines for Malaria Venture , International Center Cointrin, Entrance G, 3rd Floor, Route de Pré-Bois 20, P.O. Box 1826, CH-1215, Geneva 15, Switzerland
| | - Kevin D Read
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Ian H Gilbert
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| |
Collapse
|
10
|
A green four-component synthesis of 2-amino-3-cyano-4-aryl-6-sulfanepyrimidine in water solvent using phase-transfer catalyst. JOURNAL OF THE IRANIAN CHEMICAL SOCIETY 2015. [DOI: 10.1007/s13738-015-0770-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Preti D, Baraldi PG, Moorman AR, Borea PA, Varani K. History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents. Med Res Rev 2015; 35:790-848. [PMID: 25821194 DOI: 10.1002/med.21344] [Citation(s) in RCA: 77] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Growing evidence emphasizes that the purine nucleoside adenosine plays an active role as a local regulator in different pathologies. Adenosine is a ubiquitous nucleoside involved in various physiological and pathological functions by stimulating A1 , A2A , A2B , and A3 adenosine receptors (ARs). At the present time, the role of A2A ARs is well known in physiological conditions and in a variety of pathologies, including inflammatory tissue damage and neurodegenerative disorders. In particular, the use of selective A2A antagonists has been reported to be potentially useful in the treatment of Parkinson's disease (PD). In this review, A2A AR signal transduction pathways, together with an analysis of the structure-activity relationships of A2A antagonists, and their corresponding pharmacological roles and therapeutic potential have been presented. The initial results from an emerging polypharmacological approach are also analyzed. This approach is based on the optimization of the affinity and/or functional activity of the examined compounds toward multiple targets, such as A1 /A2A ARs and monoamine oxidase-B (MAO-B), both closely implicated in the pathogenesis of PD.
Collapse
Affiliation(s)
- Delia Preti
- Department of Chemical and Pharmaceutical Sciences, University of Ferrara, 44121, Ferrara, Italy
| | - Pier Giovanni Baraldi
- Department of Chemical and Pharmaceutical Sciences, University of Ferrara, 44121, Ferrara, Italy
| | | | - Pier Andrea Borea
- Section of Pharmacology, Department of Medical Science, University of Ferrara, 44121, Ferrara, Italy
| | - Katia Varani
- Section of Pharmacology, Department of Medical Science, University of Ferrara, 44121, Ferrara, Italy
| |
Collapse
|
12
|
Thiazole: a promising heterocycle for the development of potent CNS active agents. Eur J Med Chem 2014; 92:1-34. [PMID: 25544146 DOI: 10.1016/j.ejmech.2014.12.031] [Citation(s) in RCA: 112] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2014] [Revised: 11/10/2014] [Accepted: 12/18/2014] [Indexed: 01/15/2023]
Abstract
Thiazole is a valuable scaffold in the field of medicinal chemistry and has accounted to display a variety of biological activities. Thiazole and its derivatives have attracted continuing interest to design various novel CNS active agents. In the past few decades, thiazoles have been widely used to develop a variety of therapeutic agents against numerous CNS targets. Thiazole containing drug molecules are currently being used in treatment of various CNS disorders and a number of thiazole derivatives are also presently in clinical trials. A lot of research has been carried out on thiazole and their analogues, which has proved their efficacy to overcome several CNS disorders in rodent as well as primate models. The aim of present review is to highlights diverse CNS activities displayed by thiazole and their derivatives. SAR of this nucleus has also been well discussed. This review covers the recent updates present in literature and will surely provide a greater insight for the designing and development of potent thiazole based CNS active agents in future.
Collapse
|
13
|
|
14
|
Zheng J, Yang Z, Li X, Li L, Ma H, Wang M, Zhang H, Zhen X, Zhang X. Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson's disease. ACS Chem Neurosci 2014; 5:674-82. [PMID: 24922583 DOI: 10.1021/cn5000716] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Parkinson's disease is a neurodegenerative disease characterized by the motor symptoms of bradykinesia, tremor, and rigidity. Current therapies are based mainly on dopaminergic replacement strategies by administration of either dopamine agonists or dopamine precursor levodopa (L-Dopa). These treatments provide symptomatic relief without slowing or stopping the disease progression, and long-term usage of these drugs is associated with diminished efficacy, motor fluctuation, and dyskinisia. Unfortunately, there had been few novel treatments developed in the past decades. Among nondopaminergic strategies for the treatment of Parkinson's disease, antagonism of the adenosine A2A receptor has emerged to show great potential. Here we report the optimization of a new chemical scaffold, which achieved exceptional receptor binding affinity and ligand efficiency against adenosine A2A receptor. The leading compounds demonstrated excellent efficacy in the haloperidol induced catalepsy model for Parkinson's disease.
Collapse
Affiliation(s)
- Jiyue Zheng
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psycho-Diseases and College
of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Zhaohui Yang
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psycho-Diseases and College
of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Xuan Li
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psycho-Diseases and College
of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Linlang Li
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psycho-Diseases and College
of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Haikuo Ma
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psycho-Diseases and College
of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Meiyu Wang
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psycho-Diseases and College
of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Hongjian Zhang
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psycho-Diseases and College
of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Xuechu Zhen
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psycho-Diseases and College
of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| | - Xiaohu Zhang
- Jiangsu Key Laboratory of
Translational Research and Therapy for Neuro-Psycho-Diseases and College
of Pharmaceutical Sciences, Soochow University, Su Zhou, Jiangsu 215021, P. R. China
| |
Collapse
|
15
|
Bisson J, Dehaudt J, Charbonnel M, Guillaneux D, Miguirditchian M, Marie C, Boubals N, Dutech G, Pipelier M, Blot V, Dubreuil D. 1,10‐Phenanthroline and Non‐Symmetrical 1,3,5‐Triazine Dipicolinamide‐Based Ligands For Group Actinide Extraction. Chemistry 2014; 20:7819-29. [DOI: 10.1002/chem.201402266] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2014] [Indexed: 11/09/2022]
Affiliation(s)
- Julia Bisson
- CEA‐Nuclear Division Energy, Radiochemistry & Process Department, 30207 Bagnols‐sur‐Cèze (France)
- Université de Nantes, CEISAM UMR‐CNRS 6230, UFR des Sciences et Techniques, 2 rue de la Houssiniere BP 92208, 44322 Nantes Cedex 3 (France)
| | - Jérémy Dehaudt
- Université de Nantes, CEISAM UMR‐CNRS 6230, UFR des Sciences et Techniques, 2 rue de la Houssiniere BP 92208, 44322 Nantes Cedex 3 (France)
| | | | - Denis Guillaneux
- CEA‐Nuclear Division Energy, Radiochemistry & Process Department, 30207 Bagnols‐sur‐Cèze (France)
| | - Manuel Miguirditchian
- CEA‐Nuclear Division Energy, Radiochemistry & Process Department, 30207 Bagnols‐sur‐Cèze (France)
| | - Cécile Marie
- CEA‐Nuclear Division Energy, Radiochemistry & Process Department, 30207 Bagnols‐sur‐Cèze (France)
| | - Nathalie Boubals
- CEA‐Nuclear Division Energy, Radiochemistry & Process Department, 30207 Bagnols‐sur‐Cèze (France)
| | - Guy Dutech
- CEA‐Nuclear Division Energy, Radiochemistry & Process Department, 30207 Bagnols‐sur‐Cèze (France)
| | - Muriel Pipelier
- Université de Nantes, CEISAM UMR‐CNRS 6230, UFR des Sciences et Techniques, 2 rue de la Houssiniere BP 92208, 44322 Nantes Cedex 3 (France)
| | - Virginie Blot
- Université de Nantes, CEISAM UMR‐CNRS 6230, UFR des Sciences et Techniques, 2 rue de la Houssiniere BP 92208, 44322 Nantes Cedex 3 (France)
| | - Didier Dubreuil
- Université de Nantes, CEISAM UMR‐CNRS 6230, UFR des Sciences et Techniques, 2 rue de la Houssiniere BP 92208, 44322 Nantes Cedex 3 (France)
| |
Collapse
|
16
|
Yang Z, Li X, Ma H, Zheng J, Zhen X, Zhang X. Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists. Bioorg Med Chem Lett 2013; 24:152-5. [PMID: 24332624 DOI: 10.1016/j.bmcl.2013.11.051] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Revised: 11/18/2013] [Accepted: 11/21/2013] [Indexed: 10/25/2022]
Abstract
We have previously reported a series of 2,4,6-trisubstituted pyrimidines as potent A2A receptor antagonists. The leading compounds often feature a potentially labile acetamide functional group which tends to hydrolyze under acidic conditions. Here we report the replacement of the acetamide functional group with bioisosteres. This effort led us to a new series of adenosine A2A receptor antagonists with improved potency and chemical stability.
Collapse
Affiliation(s)
- Zhaohui Yang
- Jiangsu Key Laboratory of Translational Research and Experimental Therapy for Neuro-Psycho-Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021, P. R. China
| | - Xuan Li
- Jiangsu Key Laboratory of Translational Research and Experimental Therapy for Neuro-Psycho-Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021, P. R. China
| | - Haikuo Ma
- Jiangsu Key Laboratory of Translational Research and Experimental Therapy for Neuro-Psycho-Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021, P. R. China
| | - Jiyue Zheng
- Jiangsu Key Laboratory of Translational Research and Experimental Therapy for Neuro-Psycho-Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021, P. R. China
| | - Xuechu Zhen
- Jiangsu Key Laboratory of Translational Research and Experimental Therapy for Neuro-Psycho-Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021, P. R. China
| | - Xiaohu Zhang
- Jiangsu Key Laboratory of Translational Research and Experimental Therapy for Neuro-Psycho-Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021, P. R. China.
| |
Collapse
|
17
|
de Lera Ruiz M, Lim YH, Zheng J. Adenosine A2A Receptor as a Drug Discovery Target. J Med Chem 2013; 57:3623-50. [DOI: 10.1021/jm4011669] [Citation(s) in RCA: 204] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
- Manuel de Lera Ruiz
- Department
of Chemical Research, Merck Research Laboratories, 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Yeon-Hee Lim
- Department
of Chemical Research, Merck Research Laboratories, 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Junying Zheng
- Department
of Chemical Research, Merck Research Laboratories, 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States
| |
Collapse
|
18
|
An efficient synthesis of enantiopure (R)-heteroarylpyrimidine analogs. Molecules 2013; 18:11144-52. [PMID: 24029747 PMCID: PMC6270617 DOI: 10.3390/molecules180911144] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Revised: 09/03/2013] [Accepted: 09/04/2013] [Indexed: 12/20/2022] Open
Abstract
An efficient synthesis of enantiopure (R)-heteroarylpyrimidine analogs is described here, which involves introduction of a chiral group, formation and separation of diasteroisomers and final transformation of an amide to an ester. The absolute configuration of the enantiopure HAPs is confirmed by X-ray analysis of their intermediates.
Collapse
|
19
|
Bushuev MB, Gatilov YV, Nikolaenkova EB, Vasiliev VG, Krivopalov VP. Mono-, di-, tetra- and heptanuclear copper(II) complexes with 4-(3,5-di-R-1H-pyrazol-1-yl)-6-methyl-2-(pyridin-2-yl)pyrimidines (R=H, Me): Syntheses, crystal structures and electrospray ionization mass spectrometry. Inorganica Chim Acta 2013. [DOI: 10.1016/j.ica.2012.10.018] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Bushuev MB, Gatilov YV, Krivopalov VP, Nikolaenkova EB. Copper(II) complex with 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(pyridin-2-yl)pyrimidin-4-amine: synthesis, crystal structure, and electronic spectroscopy. J COORD CHEM 2012. [DOI: 10.1080/00958972.2012.657187] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Affiliation(s)
- Mark B. Bushuev
- a Nikolaev Institute of Inorganic Chemistry , Siberian Branch of Russian Academy of Sciences , 3, Akad. Lavrentiev Ave., Novosibirsk 630090 , Russia
- b Department of Natural Sciences , Novosibirsk State University (National Research University) , 2, Pirogova str., Novosibirsk 630090 , Russia
| | - Yuri V. Gatilov
- c N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of Russian Academy of Sciences , Novosibirsk , Russia
| | - Viktor P. Krivopalov
- c N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of Russian Academy of Sciences , Novosibirsk , Russia
| | - Elena B. Nikolaenkova
- c N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of Russian Academy of Sciences , Novosibirsk , Russia
| |
Collapse
|
21
|
Shook BC, Jackson PF. Adenosine A(2A) Receptor Antagonists and Parkinson's Disease. ACS Chem Neurosci 2011; 2:555-67. [PMID: 22860156 DOI: 10.1021/cn2000537] [Citation(s) in RCA: 84] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2011] [Accepted: 06/21/2011] [Indexed: 11/28/2022] Open
Abstract
This Review summarizes and updates the work on adenosine A(2A) receptor antagonists for Parkinson's disease from 2006 to the present. There have been numerous publications, patent applications, and press releases within this time frame that highlight new medicinal chemistry approaches to this attractive and promising target to treat Parkinson's disease. The Review is broken down by scaffold type and will discuss the efforts to optimize particular scaffolds for activity, pharmacokinetics, and other drug discovery parameters. The majority of approaches focus on preparing selective A(2A) antagonists, but a few approaches to dual A(2A)/A(1) antagonists will also be highlighted. The in vivo profiles of compounds will be highlighted and discussed to compare activities across different chemical series. A clinical report and update will be given on compounds that have entered clinical trials.
Collapse
Affiliation(s)
- Brian C. Shook
- Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Welsh and McKean Roads, P.O. Box 776, Spring House, Pennsylvania 19477, United States
| | - Paul F. Jackson
- Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Welsh and McKean Roads, P.O. Box 776, Spring House, Pennsylvania 19477, United States
| |
Collapse
|
22
|
Sams AG, Mikkelsen GK, Larsen M, Langgård M, Howells ME, Schrøder TJ, Brennum LT, Torup L, Jørgensen EB, Bundgaard C, Kreilgård M, Bang-Andersen B. Discovery of Phosphoric Acid Mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} Ester (Lu AA47070): A Phosphonooxymethylene Prodrug of a Potent and Selective hA2A Receptor Antagonist. J Med Chem 2011; 54:751-64. [DOI: 10.1021/jm1008659] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Anette G. Sams
- Medicinal Chemistry Research, Lundbeck Research Denmark, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen Valby, Denmark
| | - Gitte K. Mikkelsen
- Medicinal Chemistry Research, Lundbeck Research Denmark, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen Valby, Denmark
| | - Mogens Larsen
- Medicinal Chemistry Research, Lundbeck Research Denmark, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen Valby, Denmark
| | - Morten Langgård
- Computational Chemistry, Lundbeck Research Denmark, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen Valby, Denmark
| | - Mark E. Howells
- Process Research, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen Valby, Denmark
| | - Tenna J. Schrøder
- Molecular Pharmacology, Lundbeck Research Denmark, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen Valby, Denmark
| | - Lise T. Brennum
- In vivo Neuropharmacology, Lundbeck Research Denmark, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen Valby, Denmark
| | - Lars Torup
- In vivo Neuropharmacology, Lundbeck Research Denmark, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen Valby, Denmark
| | - Erling B. Jørgensen
- Preformulation, Lundbeck Research Denmark, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen Valby, Denmark
| | - Christoffer Bundgaard
- Discovery ADME, Lundbeck Research Denmark, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen Valby, Denmark
| | - Mads Kreilgård
- Discovery ADME, Lundbeck Research Denmark, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen Valby, Denmark
| | - Benny Bang-Andersen
- Medicinal Chemistry Research, Lundbeck Research Denmark, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen Valby, Denmark
| |
Collapse
|
23
|
Shook BC, Charavarty D, Barbay JK, Wang A, Leonard K, Alford V, Powell M, Beauchamp DA, Rassnick S, Scannevin R, Carroll K, Wallace N, Crooke J, Ault M, Lampron L, Westover L, Rhodes K, Jackson PF. Aminomethyl substituted thieno[2,3-d]pyrimidines as adenosine A2A receptor antagonists. MEDCHEMCOMM 2011. [DOI: 10.1039/c1md00082a] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
24
|
Yaziji V, Coelho A, El Maatougui A, Brea J, Loza MI, Garcia-Mera X, Sotelo E. Divergent solution-phase synthesis of diarylpyrimidine libraries as selective A3 adenosine receptor antagonists. ACTA ACUST UNITED AC 2010; 11:519-22. [PMID: 19472983 DOI: 10.1021/cc900044k] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
A practical and divergent solution-phase synthetic strategy has been optimized to prepare a highly diverse library of 2,4-diaryl- and 2,6-diarylpyrimidines. Structural elaboration of the starting heterocyclic scaffolds was accomplished by exploiting the potential for diversity offered by the Suzuki-Miyaura cross-coupling reaction. These studies enabled the identification of structurally simple, highly potent, and selective A(3) adenosine receptor antagonists.
Collapse
Affiliation(s)
- Vicente Yaziji
- Combinatorial Chemistry Unit and Screening Unit, Institute of Industrial Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain
| | | | | | | | | | | | | |
Collapse
|
25
|
Zhu X, Zhao G, Zhou X, Xu X, Xia G, Zheng Z, Wang L, Yang X, Li S. 2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly. Bioorg Med Chem Lett 2010; 20:299-301. [DOI: 10.1016/j.bmcl.2009.10.119] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2009] [Revised: 09/29/2009] [Accepted: 10/27/2009] [Indexed: 11/25/2022]
|
26
|
Lanier MC, Moorjani M, Luo Z, Chen Y, Lin E, Tellew JE, Zhang X, Williams JP, Gross RS, Lechner SM, Markison S, Joswig T, Kargo W, Piercey J, Santos M, Malany S, Zhao M, Petroski R, Crespo MI, Díaz JL, Saunders J, Wen J, O’Brien Z, Jalali K, Madan A, Slee DH. N-[6-Amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A Receptor Antagonists with Improved Drug Like Properties and in Vivo Efficacy. J Med Chem 2009; 52:709-17. [DOI: 10.1021/jm800908d] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Marion C. Lanier
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Manisha Moorjani
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Zhiyong Luo
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Yongsheng Chen
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Emily Lin
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - John E. Tellew
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Xiaohu Zhang
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - John P. Williams
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Raymond S. Gross
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Sandra M. Lechner
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Stacy Markison
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Tanya Joswig
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - William Kargo
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Jaime Piercey
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Mark Santos
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Siobhan Malany
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Marilyn Zhao
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Robert Petroski
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - María I. Crespo
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - José-Luis Díaz
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - John Saunders
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Jenny Wen
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Zhihong O’Brien
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Kayvon Jalali
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Ajay Madan
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| | - Deborah H. Slee
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, and Preclinical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, and Almirall Research Center, Almirall, Ctra. Laureà Miró, 408-410, E-08980 St. Feliu de Llobregat, Barcelona, Spain
| |
Collapse
|
27
|
Manlove A, Groziak MP. Chapter 6.2: Six-Membered Ring Systems: Diazines and Benzo Derivatives. PROGRESS IN HETEROCYCLIC CHEMISTRY 2009. [DOI: 10.1016/s0959-6380(09)70040-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
|
28
|
Abstract
The development of potent and selective agonists and antagonists of adenosine receptors (ARs) has been a target of medicinal chemistry research for several decades, and recently the US Food and Drug Administration has approved Lexiscan, an adenosine derivative substituted at the 2 position, for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Currently, some other adenosine A(2A) receptor (A(2A)AR) agonists and antagonists are undergoing preclinical testing and clinical trials. While agonists are potent antiinflammatory agents also showing hypotensive effects, antagonists are being developed for the treatment of Parkinson's disease.However, since there are still major problems in this field, including side effects, low brain penetration (for the targeting of CNS diseases), short half-life, or lack of in vivo effects, the design and development of new AR ligands is a hot research topic.This review presents an update on the medicinal chemistry of A(2A)AR agonists and antagonists, and stresses the strong need for more selective ligands at the human A(2A)AR subtype, in particular in the case of agonists.
Collapse
Affiliation(s)
- Gloria Cristalli
- Dipartimento di Scienze Chimiche, Università di Camerino, 62032 Camerino (MC), Italy.
| | | | | |
Collapse
|
29
|
Neustadt BR, Liu H, Hao J, Greenlee WJ, Stamford AW, Foster C, Arik L, Lachowicz J, Zhang H, Bertorelli R, Fredduzzi S, Varty G, Cohen-Williams M, Ng K. Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines. Bioorg Med Chem Lett 2008; 19:967-71. [PMID: 19109019 DOI: 10.1016/j.bmcl.2008.11.075] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2008] [Revised: 11/19/2008] [Accepted: 11/20/2008] [Indexed: 10/21/2022]
Abstract
Antagonism of the adenosine A(2a) receptor offers great promise in the treatment of Parkinson's disease. In the course of exploring pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine A(2A) antagonists, which led to clinical candidate SCH 420814, we prepared 1,2,4-triazolo[1,5-c]pyrimidines with potent and selective (vs A(1)) A(2a) antagonist activity, including oral activity in the rat haloperidol-induced catalepsy model. Structure-activity relationships and plasma levels are described for this series.
Collapse
Affiliation(s)
- Bernard R Neustadt
- Department of Chemical Research, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033-1310, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Zhang X, Tellew JE, Luo Z, Moorjani M, Lin E, Lanier MC, Chen Y, Williams JP, Saunders J, Lechner SM, Markison S, Joswig T, Petroski R, Piercey J, Kargo W, Malany S, Santos M, Gross RS, Wen J, Jalali K, O’Brien Z, Stotz CE, Crespo MI, Díaz JL, Slee DH. Lead Optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A Adenosine Receptor Antagonists for the Treatment of Parkinson’s Disease. J Med Chem 2008; 51:7099-110. [DOI: 10.1021/jm800851u] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Xiaohu Zhang
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - John E. Tellew
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Zhiyong Luo
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Manisha Moorjani
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Emily Lin
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Marion C. Lanier
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Yongsheng Chen
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - John P. Williams
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - John Saunders
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Sandra M. Lechner
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Stacy Markison
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Tanya Joswig
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Robert Petroski
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Jaime Piercey
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - William Kargo
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Siobhan Malany
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Mark Santos
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Raymond S. Gross
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Jenny Wen
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Kayvon Jalali
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Zhihong O’Brien
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Carol E. Stotz
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - María I. Crespo
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - José-Luis Díaz
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| | - Deborah H. Slee
- Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development, and Pharmaceutical Development, Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130, Almirall Research Center, Almirall, Ctra. Laureà Miró, E-08980 St. Feliu de Llobregat, 408-410 Barcelona, Spain
| |
Collapse
|
31
|
2,6-Diaryl-4-acylaminopyrimidines as potent and selective adenosine A2A antagonists with improved solubility and metabolic stability. Bioorg Med Chem Lett 2008; 18:5402-5. [DOI: 10.1016/j.bmcl.2008.09.048] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2008] [Revised: 09/11/2008] [Accepted: 09/11/2008] [Indexed: 11/22/2022]
|
32
|
Slee DH, Moorjani M, Zhang X, Lin E, Lanier MC, Chen Y, Rueter JK, Lechner SM, Markison S, Malany S, Joswig T, Santos M, Gross RS, Williams JP, Castro-Palomino JC, Crespo MI, Prat M, Gual S, Díaz JL, Jalali K, Sai Y, Zuo Z, Yang C, Wen J, O'Brien Z, Petroski R, Saunders J. 2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships. J Med Chem 2008; 51:1730-9. [PMID: 18307293 DOI: 10.1021/jm701187w] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Previously we have described a series of novel A 2A receptor antagonists with excellent water solubility. As described in the accompanying paper, the antagonists were first optimized to remove an unsubstituted furyl moiety, with the aim of avoiding the potential metabolic liabilities that can arise from the presence of an unsubstituted furan. This effort identified a series of potent and selective methylfuryl derivatives. Herein, we describe the further optimization of this series to increase potency, maintain selectivity for the human A 2A vs the human A 1 receptor, and minimize activity against the hERG channel. In addition, the observed structure-activity relationships against both the human and the rat A 2A receptor are reported.
Collapse
Affiliation(s)
- Deborah H Slee
- Department of Medicinal Chemistry, Neurocrine Biosciences, 12790 El Camino Real, San Diego, CA 92130, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|